ArticleFrontiers in medicine2025
Fibrinogen-to-albumin ratio: a new biomarker to identify inflammatory bowel disease in active stage.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- C-Reactive Protein-to-Albumin Ratio in Pediatric Inflammatory Bowel Disease: Associations with Disease Activity and Comparison with C-Reactive Protein Alone.Diagnostics (Basel, Switzerland) · 2026Article
- Fibrinogen in extracellular matrix remodeling: functional switching, source heterogeneity, and biomaterial translation.Frontiers in cell and developmental biology · 2026Review
- Association between fibrinogen-to-albumin ratio and all-cause mortality in critically ill patients with atrial fibrillation: a retrospective study using the MIMIC-IV database.European journal of medical research · 2025Article
- The potential value of fibrinogen-to-albumin ratio in assessing disease activity in rheumatoid arthritis.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The objective of our study was to externally validate the value of the fibrinogen-to-albumin ratio (FAR), a new biomarker used to identify active inflammatory bowel disease (IBD). Materials and methods: A total of 245 ulcerative colitis (UC) and 543 Crohn's disease (CD) patients were included in our study. Multivariate logistic regression analysis was used to investigate the independent association between FAR and disease activity in patients with UC or CD. The area under the receiver operating characteristic curve was used to assess the prediction accuracy of biomarkers in distinguishing disease states. Results: Multivariate logistic regression analysis identified the FAR as the strongest predictor to discriminate disease activity of UC (odds ratio: 24.871, 95% confidence interval: 9.831-38.912, Conclusion: The FAR, a simple prognostic indicator, performs well in identifying active IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.